Patents by Inventor Jean-Pierre Kraehenbuhl

Jean-Pierre Kraehenbuhl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060257415
    Abstract: A method is provided for inducing the adaptive immune response of a patient to an antigen comprising administering to the patient an effective amount of a flagellin protein or peptide fragment thereof to induce an adaptive immune response to said antigen.
    Type: Application
    Filed: September 3, 2003
    Publication date: November 16, 2006
    Applicant: FONDATION EUROV ACC
    Inventors: Jean-Claude Sirard, Jean-Pierre Kraehenbuhl
  • Publication number: 20040115212
    Abstract: This application relates to the use of attenuated prokaryotic microorganism strains (such as Salmonella) expressing nucleic acid encoding HPV proteins as vaccines against HPV infection and the associated increased risk of cancer. In particular, the work shows that it is possible to assemble VLPs in a prokaryotic organism and that nasal immunization of mice with the strains HPV-specific conformationally dependent and neutralizing antibodies in serum and genital secretions. The experiments described herein show that it is also possible to assemble chimeric VLPs of a HPV including a fusion partner and that tumour protection can be induced.
    Type: Application
    Filed: September 22, 2003
    Publication date: June 17, 2004
    Applicant: BTG International Limited
    Inventors: Denise N. Haefliger, Jean-Pierre Kraehenbuhl
  • Publication number: 20030124143
    Abstract: A purified immunogenic polypeptide comprises an epitope unit recognized by a protective monoclonal antibody having a high affinity and a high specificity for a surface polysaccharide of a pathogenic microorganism of bacterial, viral, or fungal origin. The polypeptide is capable of inducing an immune response in vivo against the pathogenic microorganism. The immune response confers protection in mice against challenge with the virulent microorganisms.
    Type: Application
    Filed: November 22, 2002
    Publication date: July 3, 2003
    Inventors: Armelle Phalipon, Philippe Sansonetti, Franco Felici, Riccardo Cortese, Jean Pierre Kraehenbuhl
  • Patent number: 6541000
    Abstract: A method for generating antigen-sensitized Ig-A-producing lymphoblasts in a mammal, using an immunogen comprising an antigen or antigen mixture in association with hydroxylated calcium phosphate (hydroxy apatite) is administered to a mucosal surface of the mammal.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: April 1, 2003
    Assignees: President & Fellows of Harvard College, Institut Suisse de Recherche Experimentale sur le Cancer
    Inventors: Helen M. Amerongen, Marian R. Neutra, Jean-Pierre Kraehenbuhl
  • Patent number: 6528061
    Abstract: A purified immunogenic polypeptide comprises an epitope unit recognized by a protective monoclonal antibody having a high affinity and a high specificity for a surface polysaccharide of a pathogenic microorganism of bacterial, viral, or fungal origin. The polypeptide is capable of inducing an immune response in vivo against the pathogenic microorganism. The immune response confers protection in mice against challenge with the virulent microorganisms.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: March 4, 2003
    Inventors: Armelle Phalipon, Philippe Sansonetti, Franco Felici, Riccardo Cortese, Jean Pierre Kraehenbuhl
  • Publication number: 20030007980
    Abstract: Method of eliciting in a mammalian host a protective immune response to Helicobacter infection and treatment of Helicobacter infection by administering to the host an immunogenically effective amount of a Helicobacter urease or urease subunits as antigen. Vaccine compositions are also provided.
    Type: Application
    Filed: September 18, 2001
    Publication date: January 9, 2003
    Inventors: Pierre Michetti, Irene Corthesy-Theulaz, Andre Blum, Catherine Davin, Rainer Haas, Jean-Pierre Kraehenbuhl, Emilia Saraga
  • Patent number: 6458368
    Abstract: Attenuated strain of a prokaryotic microorganism, being an attenuated strain of Salmonella suitable for use in a live vaccine for administration to a human or animal, in which the microorganism is transformed with nucleic acid encoding Human papilloma virus 16 L1 major capsid protein. The protein assembles in the microorganism to form virus-like particles (VLPs) that are capable of illiciting an immune response sufficient to produce neutralizing antibodies in serum and genital secretions specific for Human papilloma 16 infection when the microorganism is administered to the human or animal body.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: October 1, 2002
    Assignee: BTG International Limited
    Inventors: Denise Nardelli Haefliger, Jean-Pierre Kraehenbuhl
  • Publication number: 20020025328
    Abstract: This application relates to the use of attenuated prokaryotic microorganism strains (such as Salmonella ) expressing nucleic acid encoding HPV proteins as vaccines against HPV infection and the associated increased risk of cancer. In particular, the work shows that it is possible to assemble VLPs in a prokaryotic organism and that nasal immunization of mice with the strains HPV-specific conformationally dependent and neutralizing antibodies in serum and genital secretions. The experiments described herein show that it is also possible to assemble chimeric VLPs of an HPV including a fusion partner and that tumor protection can be induced.
    Type: Application
    Filed: April 9, 1999
    Publication date: February 28, 2002
    Inventors: DENISE NARDELLI HAEFLIGER, JEAN-PIERRE KRAEHENBUHL
  • Publication number: 20010029043
    Abstract: This application relates to the use of attenuated prokaryotic miccrooganism strains (such as Salmonella) expressing nucleic acid encoding HPV proteins as vaccines against HPV infection and the associated increased risk of cancer. In particular, the work shows that it is possible to assemble VLPs in a prokaryotic organism and that nasal immunization of mice with the strains HPV-specific conformationally dependent and neutralizing antibodies in serum and genital secretions. The experiments described herein show that it is also possible to assemble chimeric VLPs of a HPV including a fusion partner and that tumour protection can be induced.
    Type: Application
    Filed: January 29, 2001
    Publication date: October 11, 2001
    Applicant: BTG International Limited
    Inventors: Denise N. Haefliger, Jean-Pierre Kraehenbuhl
  • Patent number: 6290962
    Abstract: Method of eliciting in a mammalian host a protective immune response to Helicobacter infection and treatment of Helicobacter infection by administering to the host an immunogenically effective amount of a Helicobacter urease or urease subunits as antigen. Vaccine compositions are also provided.
    Type: Grant
    Filed: February 23, 1994
    Date of Patent: September 18, 2001
    Assignee: OraVax, Inc.
    Inventors: Pierre Michetti, Iréne Corthésy-Theulaz, André Blum, Catherine Davin, Rainier Haas, Jean-Pierre Kraehenbuhl, Emilia Saraga
  • Patent number: 6258529
    Abstract: The invention features methods for isolating immunoglobulin variable region genes, and the use of these genes in the production of chimeric and isotype switched antibodies. The invention also features substantially pure DNA encoding a variable region of the antibody produced by hybridoma cell line HNK-20, and chimeric antibodies containing this variable region.
    Type: Grant
    Filed: December 1, 1994
    Date of Patent: July 10, 2001
    Assignee: OraVax, Inc.
    Inventors: José Berdoz, Jean-Pierre Kraehenbuhl
  • Patent number: 6251406
    Abstract: This application relates to the use of attenuated prokaryotic miccrooganism strains (such as Salmonella) expressing nucleic acid encoding HPV proteins as vaccines against HPV infection and he associated increased risk of cancer. In particular, the work shows that it is possible to assemble VLPs in a prokaryotic organism and that nasal immunization of mice with the strains HPV-specific conformationally dependent and neutralizing antibodies in serum and genital secretions. The experiments described herein show that it is also possible to assemble chimeric VLPs of a HPV including a fusion partner and that tumor protection can be induced.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: June 26, 2001
    Assignee: BTG International Limited
    Inventors: Denise N. Haefliger, Jean-Pierre Kraehenbuhl
  • Patent number: 5972336
    Abstract: Method of eliciting in a mammalian host a protective immune response to Helicobacter infection by administering to the host an immunogenically effective amount of a Helicobacter urease or urease subunits as antigen. Vaccine compositions are also provided.
    Type: Grant
    Filed: July 6, 1993
    Date of Patent: October 26, 1999
    Assignee: OraVax Merieux Co.
    Inventors: Pierre Michetti, Andre Blum, Catherine Davin, Rainer Haas, Irene Corthesy-Theulaz, Jean-Pierre Kraehenbuhl, Emilia Saraga
  • Patent number: 5443832
    Abstract: A method for generating antigen-sensitized Ig-A-producing lymphoblasts in a mammal, using an immunogen comprising an antigen or antigen mixture in association with hydroxylated calcium phosphate (hydroxy apatite) is administered to a mucosal surface of the mammal.
    Type: Grant
    Filed: April 16, 1990
    Date of Patent: August 22, 1995
    Assignee: Institut Swisse de Recherches Experimentales sur le Cancer
    Inventors: Helen M. Amerongen, Marian R. Neutra, Jean-Pierre Kraehenbuhl